Kanser Hastalarında İnterlökin-2 Kullanımı ve Hemşirelik Yönetimi

Yıl 2015, Cilt: 2 Sayı: 3, 49 - 59, 22.03.2016

Sevgisun Kapucu

Öz

Günümüzde biyolojik ajanlar başta onkoloji olmak üzere birçok klinik alanda kullanılmaktadır. Gelişen bu alanda, biyolojik ajanların uygulanması ve biyolojik tedavi alan hastanın yönetimi ile ilgili sağlık ekibi içerisinde hemşirelere büyük sorumluluklar düşmektedir. Bu yazıda, biyolojik ajanlar arasında yaygın olarak kullanılan IL-2 kullanımı ve hasta bakımında hemşirenin sorumlulukları üzerinde duruldu.

Anahtar Kelimeler

Hemşirelik, hasta yönetimi, immün sistem, interlökin-2, kanser, yan etkiler

Nursing Management and Interleukin-2 Use in Patients with Cancer

Öz

Recently, biologic agents are used frequently in various clinical settings, besides being used initially in oncology units. In these developing area, among health care team nurses have major responsibilities in administration of biologic agents and management of patients receiving biologic agents. In this review we focused on responsibilities of nurses in use and management of IL-2 which is one of the biologic agents that are commonly used.

Anahtar Kelimeler

Nursing, patient management, immune system, Interleukin-2, cancer, side effects

Kaynakça

• 1. İliçin, G. Biberoğlu, K. Süleymanlar, G. Ünal S. İç Hastalıkları, 3. Baskı, Güneş Tıp Kitapevi, 2012, Ankara.
• 2. Yarbro, CH. Wujcik, D. Gobel, BH. Cancer Nursing, Principles and Practice, 7th. Edition, Jones And Bartlett Publishers, 2011, London.
• 3. Bindon C, Czerniecki M, Ruell P, et al. Clearance rates and systemic effects of intravenously administered interleukin-2 (Il-2) containing preparations in human subjects. Br J Cancer. 1983; 47: 123–133.
• 4. Widmaier, EP. Raff, H. Strang, Kt. Çeviren: Özgünen, T. Vander İnsan Fizyolojisi, Vücud Foksiyon Mekanizmaları, 13. Baskı, Güneş Tıp Kitapevi, Ankara, 2014.
• 5. Hauschild A, Weichenthal M, Balda B-R, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003; 21: 2883–2888.
• 6. Buzaid AC. Biochemotherapy for advanced melanoma. Crit Rev Oncol/Hematol. 2002;44: 103–108.
• 7. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon-alfa2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008; 26:1–9.
• 8. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferonα2b in metastatic melanoma. Ann Oncol. 2006;17: 571–577.
• 9. Mavroukakis SA, Muehlbauer PM, White RL, Schwartzentruber DJ. Clinical pathways for managing patients receiving Interleukin-2. Clin J Oncol Nurs. 2001;5: 207–217.
• 10. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of highdose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127–3132.
• 11. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797–805.
• 12. Schwartz RN, Stover DL. Dutcher J. Managing Toxicities of High-Dose Interleukin-2 Oncology 2002; URL:http://www.cancernetwork.com/renal-cell-carcinoma/managing-toxicities-high-doseinterleukin-2#sthash.OR0anQGp.dpuf, April 5, 2014.
• 13. Prometheus Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin 2 in SITC Guidelines for Treatment of Cutaneous Melanoma, URL:http://www.nestlehealthscience.com/ newsroom/press-releases/prometheus-sitc-guidelines, April 7, 2014.
• 14. Antonio C. Buzaid AC. Atkins M. Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma, URL:http://clincancerres.aacrjournals.org/content/7/9/2611.long, April 7, 2014.
• 15. Fadıloğlu Ç. Tokem Y. Özçelik H. Biyolojik ajanların kullanımında hemşirenin sorumlulukları, TOD 2008; 23(1): 45-53.
• 16. Karadokovan, A. Eti Aslan, F. Dâhili ve Cerrahi Hastalıklarda Bakım, Geliştirilmiş Baskı, Nobel Kitapevi, Adana, 2011.
• 17. Kelle İ. Kanser tedavisinde biyotoksinler, Dicle Tıp Dergisi, 2007; 34(3): 226-232.
• 18. Erol, Ç. (Ed.). İç Hastalıkları, 1. Baskı, MN Medical&Nobel Ltd. Sti., Ankara, 2008.
• 19. Furuncuoğlu, Y. Dâhiliye Akıl Notları (Özet. Pratik.Referanslı), Güneş Tıp Kitapevi, Ankara, 2013.
• 20. Habermann, TM. Ghosh, Ak. Çeviri Ed.: Ünal, S. Demir, AU. Mayo Clinic İnternal Medicine Concise Textbook (Türkçesi). Güneş Tıp Kitapevi, Ankara, 2009.
• 21. Ignatavicius, DD. Workman, MN. Medical-Surgical Nursing, Patient-Centered Collaborative Care, 6 Edition, Saunders Elsevier, USA, 2010.
• 22. Oliveria, GHM, Nesbitt, GC, Murphy, JG. Çeviri Ed. Ünal, S. Cankurtaran, M. Mayo Clinic Medical Manual (Türkçe), Güneş Tıp Kitapevi, Ankara, 2010.
• 23. Runge, MS. Greganti, MA. Çeviri Ed.: Ünal, S. Demir, M. Netter İç Hastalıkları, Güneş Tıp Kitapevi, Ankara, 2009.